(Q63844799)
Statements
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease (English)
0 references
January 2013
0 references
August 2015
0 references
296
0 references
50 year
0 references
95 year
0 references